NCT01083342 is a Phase 2 clinical trial of MTX, MVD, VIA in CNS Lymphoma, sponsored by Samsung Medical Center.

Who is sponsoring NCT01083342?

NCT01083342 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT01083342?

Interventions in NCT01083342: MTX, MVD, VIA.

What condition does NCT01083342 study?

NCT01083342 studies CNS Lymphoma.

Is NCT01083342 still recruiting?

NCT01083342 is currently completed. Last updated 22 May 2012.

Last reviewed 2012-05-22 · How we verify

NCT01083342

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open-labeled, Multicenter Phase II Study of High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study

Completed Phase 2 Last updated 22 May 2012

What this trial tests

Phase 2 trial testing MTX, MVD, VIA in CNS Lymphoma in 36 participants. Completed in 1 May 2012.

Timeline

1 January 2010

Primary endpoint
1 May 2012

1 May 2012

Quick facts

Lead sponsor	Samsung Medical Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	1 January 2010
Primary completion	1 May 2012
Estimated completion	1 May 2012
Sites	1 location across South Korea

Drugs / interventions tested

MTX, MVD, VIA — full drug profile →

Conditions studied

CNS Lymphoma — all drugs for CNS Lymphoma →

Sponsor

Samsung Medical Center

Who can join

Adults 20 to 70, any sex, with CNS Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To evaluate the complete response (CR) after chemotherapy
Time frame: 24 months

Sponsor's own description

The purpose of this study is to evaluate the complete response (CR) rate after HD-MTX induction chemotherapy followed by alternative HD MTX-based and HD Cytarabine-based combination consolidation chemotherapy

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for CNS Lymphoma

Currently open trials in the same condition.

NCT06730542 — Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma · Phase 1 · recruiting
NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT06876688 — Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma · Phase 2 · recruiting
NCT06132737 — [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients · Phase 1, PHASE2 · recruiting
NCT05926427 — Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Ner · Phase 2 · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01083342 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 22 May 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01083342.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing